Besides, the risk score was elevated in the high-grade, IDH wild-type, and 1p19q non-codeletion subtype of glioma in the validation cohort (p < 0.05), which was consistent with the training cohort (Figures 5J–L). This evidence concerns the gene IDH1 and central nervous system cancer.